Education
About Us
Working with TipRanks
Follow Us
Celyad Sa otc (CLYYF)
:CLYYF
CLYYF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.25 - $0.68
Previous CloseN/A
Volume2.42K
Average Volume (3M)17.00
Market Cap
$24.67M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)0.00
Price to Earnings (P/E)―
Beta-0.20
Next Earnings
Apr 02, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding41,428,574
10 Day Avg. Volume0
30 Day Avg. Volume17
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CLYYF FAQ
What was Celyad Sa otc’s price range in the past 12 months?
Celyad Sa otc lowest stock price was $0.24 and its highest was $0.68 in the past 12 months.
What is Celyad Sa otc’s market cap?
Celyad Sa otc’s market cap is $24.67M.
When is Celyad Sa otc’s upcoming earnings report date?
Celyad Sa otc’s upcoming earnings report date is Apr 02, 2025 which is in 21 days.
How were Celyad Sa otc’s earnings last quarter?
Currently, no data Available
Is Celyad Sa otc overvalued?
According to Wall Street analysts Celyad Sa otc’s price is currently Overvalued.
Does Celyad Sa otc pay dividends?
Celyad Sa otc does not currently pay dividends.
What is Celyad Sa otc’s EPS estimate?
Celyad Sa otc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Celyad Sa otc have?
Celyad Sa otc has 41,428,574 shares outstanding.
What happened to Celyad Sa otc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Celyad Sa otc?
Currently, no hedge funds are holding shares in CLYYF
---
Company Description
Celyad Sa otc
Celyad SA is a clinical-stage biopharmaceutical company, which engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
---
Technical Analysis
Advaxis
―
Northwest Biotherapeutics
―
Plus Therapeutics
―
Sorrento Therapeutics
―
BioMarin Pharmaceutical
―
---